Abstract
The study of antigen processing and presentation is critical to our understanding of the mechanisms that govern immune surveillance. A typical requirement of assays designed to examine antigen processing and presentation is the de novo biosynthesis of a model antigen. Historically, Vaccinia virus, a poxvirus closely related to Cowpox virus, has enjoyed widespread use for this purpose. Recombinant poxvirus-based expression has a number of advantages over other systems. Poxviruses accommodate the insertion of large pieces of recombinant DNA into their genome, and recombination and selection are relatively efficient. Poxviruses readily infect a variety of cell types, and they drive rapid and high levels of antigen expression. Additionally, they can be utilized in a variety of assays to study both MHC class I restricted and MHC class II restricted antigen processing and presentation. Ultimately, the numerous advantages of poxvirus recombinants have made the Vaccinia expression system a mainstay in the study of processing and presentation over the past two decades. In an attempt to address one shortcoming of Vaccinia virus while simultaneously retaining the benefits inherent to poxviruses, our laboratory has begun to engineer recombinant Ectromelia viruses. Ectromelia virus, or mousepox, is a natural pathogen of murine cells and performing experiments in the context of a natural host–pathogen relationship may elucidate unknown factors that influence epitope generation and host response. This chapter will describe several recombinant poxvirus system protocols used to study both MHC class I and class II antigen processing and presentation, as well as provide insight and troubleshooting techniques to improve the reproducibility and fidelity of these experiments.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Bennink JR, Yewdell JW, Smith GL, Moller C, Moss B (1984) Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells. Nature 311(5986):578–579
Yewdell JW, Anderson R, Cox JH, Eisenlohr LC, Esquivel F, Lapham C, Restifo NP, Bennink JR (1993) Multiple uses of viruses for studying antigen processing. Semin Virol 4:109–116
Morrison LA, Lukacher AE, Braciale VL, Fan DP, Braciale TJ (1986) Differences in antigen presentation to MHC class I-and class II-restricted influenza virus-specific cytolytic T lymphocyte clones. J Exp Med 163(4):903–921
Jaraquemada D, Marti M, Long EO (1990) An endogenous processing pathway in vaccinia virus-infected cells for presentation of cytoplasmic antigens to class II-restricted T cells. J Exp Med 172(3):947–954
Moss B (1991) Vaccinia virus: a tool for research and vaccine development. Science 252:1662–1667
Weir JP, Moss B (1984) Regulation of expression and nucleotide sequence of a late vaccinia virus gene. J Virol 51(3):662–669
Davison AJ, Moss B (1989) Structure of vaccinia virus late promoters. J Mol Biol 210(4):771–784
Davison AJ, Moss B (1989) Structure of vaccinia virus early promoters. J Mol Biol 210(4):749–769
Moss B (1990) Regulation of vaccinia virus transcription. Annu Rev Biochem 59:661–688
Carroll MW, Moss B (1997) Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 238(2):198–211
De Clercq E (2002) Cidofovir in the treatment of poxvirus infections. Antivir Res 55(1):1–13
Taddie JA, Traktman P (1993) Genetic characterization of the vaccinia virus DNA polymerase: cytosine arabinoside resistance requires a variable lesion conferring phosphonoacetate resistance in conjunction with an invariant mutation localized to the 3′–5′ exonuclease domain. J Virol 67(7):4323–4336
Baxby D (1981) Jenner’s smallpox vaccine. the riddle of the origin of vaccinia virus. Heinemann, London
Esteban DJ, Buller RM (2005) Ectromelia virus: the causative agent of mousepox. J Gen Virol 86. (Pt 10:2645–2659
Fenner F (1949) Mouse-pox; infectious ectromelia of mice; a review. J Immunol 63(4):341–373
Jackson RJ, Ramsay AJ, Christensen CD, Beaton S, Hall DF, Ramshaw IA (2001) Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J Virol 75(3):1205–1210
CDC (2008) Laboratory-acquired vaccinia exposures and infections—United States, 2005–2007. MMWR Morb Mortal Wkly Rep 57(15):401–404
Buller RM, Smith GL, Cremer K, Notkins AL, Moss B (1985) Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 317(6040):813–815
Blasco R, Moss B (1992) Role of cell-associated enveloped vaccinia virus in cell-to-cell spread. J Virol 66(7):4170–4179
Husain M, Moss B (2001) Vaccinia virus F13L protein with a conserved phospholipase catalytic motif induces colocalization of the B5R envelope glycoprotein in post-Golgi vesicles. J Virol 75(16):7528–7542
Blasco R, Moss B (1995) Selection of recombinant vaccinia viruses on the basis of plaque formation. Gene 158(2):157–162
Lorenzo MM, Galindo I, Blasco R (1995) Construction and isolation of recombinant vaccinia virus using genetic markers. Methods Mol Bio 269:15–30
Earl PL, Moss B (1993) Purification of vaccinia virus. Greene and Wiley-Interscience, New York, NY
Roscoe F, Xu R, Sigal LJ (2012) Characterization of Ectromelia virus deficient in EMV036, the homolog of vaccinia virus F13L, and its application for the rapid generation of recombinant viruses. J Virol 86(24):13501–13507
Sánchez-Puig JM, Blasco R (2005) Isolation of vaccinia MVA recombinants using the viral F13L gene as the selective marker. BioTechniques 39(5):665–670
Motta I, Lone YC, Kourilsky P (1998) In vitro induction of naive cytotoxic T lymphocytes with complexes of peptide and recombinant MHC class I molecules coated onto beads: role of TCR/ligand density. Eur J Immunol 28(11):3685–3695
Murali-Krishna K, Altman JD, Suresh M, Sourdive DJ, Zajac AJ, Miller JD, Slansky J, Ahmed R (1998) Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 8(2):177–187
Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM (1996) Phenotypic analysis of antigen-specific T lymphocytes. Science 274(5284):94–96
Wherry EJ, Puorro KA, Porgador A, Eisenlohr LC (1999) The induction of virus-specific CTL as a function of increasing epitope expression: responses rise steadily until excessively high levels of epitope are attained. J Immunol 163(7):3735–3745
Williams NS, Engelhard VH (1996) Identification of a population of CD4+ CTL that utilizes a perforin- rather than a Fas ligand-dependent cytotoxic mechanism. J Immunol 156(1):153–159
Fang M, Siciliano NA, Hersperger AR, Roscoe F, Hu A, Ma X et al (2012) Perforin-dependent CD4+ T-cell cytotoxicity contributes to control a murine poxvirus infection. Proc Natl Acad Sci U S A 109(25):9983–9988
Sanderson S, Shastri N (1994) LacZ inducible, antigen/MHC-specific T cell hybrids. Int Immunol 6(3):369–376
Karttunen J, Sanderson S, Shastri N (1992) Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T cell antigens. Proc Natl Acad Sci 89:6020–6024
Yewdell JW, Bennink JR (1989) Brefeldin A specifically inhibits presentation of protein antigens to cytotoxic T lymphocytes. Science 244(4908):1072–1075
Wherry EJ, McElhaugh MJ, Eisenlohr LC (2002) Generation of CD8(+) T cell memory in response to low, high, and excessive levels of epitope. J Immunol 168(9):4455–4461
Gallimore A, Glithero A, Godkin A, Tissot AC, Pluckthun A, Elliott T, Hengartner H, Zinkernagel R (1998) Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J Exp Med 187(9):1383–1393
Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD, Ahmed R (1998) Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 188(12):2205–2213
Picker LJ, Singh MK, Zdraveski Z, Treer JR, Waldrop SL, Bergstresser PR, Maino VC (1995) Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. Blood 86(4):1408–1419
Jin Y, Shih WK, Berkower I (1988) Human T cell response to the surface antigen of hepatitis B virus (HBsAg). Endosomal and nonendosomal processing pathways are accessible to both endogenous and exogenous antigen. J Exp Med 168(1):293–306
Tsung K, Yim JH, Marti W, Buller RM, Norton JA (1996) Gene expression and cytopathic effect of vaccinia virus inactivated by psoralen and long-wave UV light. J Virol 70(1):165–171
Acknowledgments
We thank Michael Hogan for his helpful discussions regarding MHC-II tetramers.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Forsyth, K.S., Addison, M.M., Eisenlohr, L.C. (2019). Recombinant Poxviruses: Versatile Tools for Immunological Assays. In: van Endert, P. (eds) Antigen Processing. Methods in Molecular Biology, vol 1988. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9450-2_16
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9450-2_16
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-9449-6
Online ISBN: 978-1-4939-9450-2
eBook Packages: Springer Protocols